Persistent diarrhea: 15 years experience at a tertiary care hospital.
OBJECTIVE
To determine the risk factors, causative enteric pathogens, final diagnosis and treatment outcomes of persistent diarrhea in children.


METHODS
A retrospective study of the patients who had diarrheal symptoms for at least 14 days diagnosed as persistent diarrhea (PD) and admitted at QSNICH during January 1997 and December 2011. Demographic data, risk factors, causative enteric pathogens, management and outcome were reviewed.


RESULTS
The review included 79 PD patients. Excluded were patients who were HIV seropositive, had GI anomalies and/or other underlying immune deficiencies. The demographic data showed mean age 11.42 months and male:female 56:23 (2.43:1). Feeding with infant formula before admission was 43% compared to exclusive breastfeeding that was only 10%. Normal nutritional status was found in half of the cases (52.1%) and protein energy malnutrition (PEM) was present in 42.3%. Stool for enteropathogens was positive only in 49.4% and the most common being mixed enteropathogens. Secondary lactase deficiency was the cause of PD in half (50%) of the patients. Management consisted of rehydration, intravenous antibiotics 53%, and other adjuvant therapies such as cholestyramine, zinc and probiotics. Along with rehydration, all patients received aggressive nutritional management upon admission. The diarrhea subsided in less than 7 days in about 70% of the patients.


CONCLUSIONS
The present study supports that important risk factors for PD are very young age group (especially under 1 year old), lack of breastfeeding and malnutrition. Enteropathogens were found in only about half of the patients and the most common cause of PD was secondary lactase deficiency. Most of the diarrhea subsided in less than 7 days of admission with proper management and aggressive nutrition upon admission.
Niyada
N
Vithayasai
Siriluck
S
Jennuvat
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001942:Breast Feeding; D002648:Child; D002675:Child, Preschool; D002792:Cholestyramine Resin / Q000627:therapeutic use; D003967:Diarrhea / Q000150:complications / Q000628:therapy*; D005243:Feces; D005260:Female; D005440:Fluid Therapy; D006760:Hospitalization; D006801:Humans; D007223:Infant; D007262:Infusions, Intravenous; D043322:Lactase / Q000172:deficiency; D008297:Male; D009752:Nutritional Status; D019936:Probiotics / Q000627:therapeutic use; D011502:Protein-Energy Malnutrition / Q000150:complications / Q000628:therapy*; D012189:Retrospective Studies; D012307:Risk Factors; D062606:Tertiary Care Centers; D016896:Treatment Outcome; D015032:Zinc / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D002792:Cholestyramine Resin; D043322:Lactase; D015032:Zinc